Allergy Therapeutics (AGY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allergy Therapeutics (AGY) has a cash flow conversion efficiency ratio of -2.755x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-11.71 Million ≈ $-1.42K USD) by net assets (GBX4.25 Million ≈ $516.98 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AGY market cap for the company's overall valuation and market capitalisation.
Allergy Therapeutics - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allergy Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allergy Therapeutics ranked by their cash flow conversion efficiency. Explore Allergy Therapeutics (AGY) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cemtrex Inc
NASDAQ:CETX
|
0.013x |
|
Capstone Holding Corp. Common Stock
NASDAQ:CAPS
|
-0.031x |
|
Hopening SA
PA:MLHPE
|
N/A |
|
Indosterling Technomedia Tbk
JK:TECH
|
-0.019x |
|
GLOW LIFETECH CORP.
F:9DO
|
0.001x |
|
Frp Advisory Group Plc
LSE:FRP
|
0.275x |
|
Highway Holdings Limited
NASDAQ:HIHO
|
0.015x |
|
ZhongDe Waste Technology AG
F:ZEF
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Allergy Therapeutics (2002–2025)
The table below shows the annual cash flow conversion efficiency of Allergy Therapeutics from 2002 to 2025. View today's stock price for Allergy Therapeutics for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX-28.19 Million ≈ $-3.43K |
GBX-28.72 Million ≈ $-3.49K |
1.019x | +111.76% |
| 2024-06-30 | GBX3.71 Million ≈ $451.28 |
GBX-32.14 Million ≈ $-3.91K |
-8.665x | +42.10% |
| 2023-06-30 | GBX2.07 Million ≈ $251.37 |
GBX-30.92 Million ≈ $-3.76K |
-14.964x | -3904.84% |
| 2022-06-30 | GBX37.77 Million ≈ $4.59K |
GBX-14.11 Million ≈ $-1.72K |
-0.374x | -312.95% |
| 2021-06-30 | GBX48.53 Million ≈ $5.91K |
GBX8.52 Million ≈ $1.04K |
0.175x | -37.42% |
| 2020-06-30 | GBX43.78 Million ≈ $5.33K |
GBX12.28 Million ≈ $1.49K |
0.280x | +88.05% |
| 2019-06-30 | GBX37.56 Million ≈ $4.57K |
GBX5.60 Million ≈ $681.36 |
0.149x | +190.33% |
| 2018-06-30 | GBX23.03 Million ≈ $2.80K |
GBX-3.80 Million ≈ $-462.59 |
-0.165x | -2878.67% |
| 2017-06-30 | GBX29.96 Million ≈ $3.65K |
GBX178.00K ≈ $21.66 |
0.006x | +101.52% |
| 2016-06-30 | GBX30.32 Million ≈ $3.69K |
GBX-11.84 Million ≈ $-1.44K |
-0.390x | -530.91% |
| 2015-06-30 | GBX34.47 Million ≈ $4.19K |
GBX3.12 Million ≈ $379.98 |
0.091x | -37.14% |
| 2014-06-30 | GBX15.07 Million ≈ $1.83K |
GBX2.17 Million ≈ $264.39 |
0.144x | -13.04% |
| 2013-06-30 | GBX14.67 Million ≈ $1.79K |
GBX2.43 Million ≈ $295.90 |
0.166x | -16.01% |
| 2012-06-30 | GBX14.59 Million ≈ $1.78K |
GBX2.88 Million ≈ $350.41 |
0.197x | +120.83% |
| 2011-06-30 | GBX2.14 Million ≈ $260.25 |
GBX-2.03 Million ≈ $-246.63 |
-0.948x | -316.36% |
| 2010-06-30 | GBX3.89 Million ≈ $472.81 |
GBX1.70 Million ≈ $207.08 |
0.438x | +2206.97% |
| 2009-06-30 | GBX-23.18 Million ≈ $-2.82K |
GBX-440.00K ≈ $-53.54 |
0.019x | -98.89% |
| 2008-06-30 | GBX-11.29 Million ≈ $-1.37K |
GBX-19.32 Million ≈ $-2.35K |
1.711x | +177.93% |
| 2007-06-30 | GBX8.60 Million ≈ $1.05K |
GBX-18.88 Million ≈ $-2.30K |
-2.196x | -786.27% |
| 2006-06-30 | GBX32.70 Million ≈ $3.98K |
GBX-8.10 Million ≈ $-985.90 |
-0.248x | -8630.66% |
| 2005-06-30 | GBX20.08 Million ≈ $2.44K |
GBX-57.00K ≈ $-6.94 |
-0.003x | -101.05% |
| 2004-06-30 | GBX7.08 Million ≈ $860.94 |
GBX1.91 Million ≈ $231.91 |
0.269x | -28.68% |
| 2003-06-30 | GBX5.55 Million ≈ $674.91 |
GBX2.10 Million ≈ $254.90 |
0.378x | -17.28% |
| 2002-06-30 | GBX-4.40 Million ≈ $-535.11 |
GBX-2.01 Million ≈ $-244.32 |
0.457x | -- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more